Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027906 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
A Phase 1 study of Prevention of Rejection in Kidney Transplant, sponsored by Eledon Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 9
- Study locations
NCT05027906: Recruiting Phase 1 study of Prevention of Rejection in Kidney Transplant, sponsored by Eledon Pharmaceuticals.
NCT05027906 is a Phase 1 study of Prevention of Rejection in Kidney Transplant that is actively recruiting participants, run by Eledon Pharmaceuticals. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05027906, a Phase 1 study of Prevention of Rejection in Kidney Transplant, is actively recruiting participants, sponsored by Eledon Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
Primary Outcome
Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and Adverse Events of Special Interest (AESIs)
Conditions Studied
Interventions
- DRUG AT-1501
Study Locations (9)
Other
- Fundação Oswaldo Ramos - Hospital do Rim - São Paulo
- Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital - Liverpool
- Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital - Oxford
British Columbia
- Providence Health Care - St. Paul's Hospital - Vancouver
- Vancouver General Hospital - Vancouver
Ohio
- University of Cincinnati - Cincinnati
New South Wales
- Royal Prince Alfred Hospital - Camperdown
South Australia
- Royal Adelaide Hospital - Adelaide
Quebec
- McGill University Health Care Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT05027906 shows while recruiting
NCT05027906 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Prevention of Rejection in Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which AT-1501 is the first listed.
NCT05027906 lists 9 locations in 6 states (Other, British Columbia, Ohio).
Frequently Asked Questions
What is clinical trial NCT05027906 about?
NCT05027906 is a clinical study titled "Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant". This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
What is the current status of trial NCT05027906?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-02-18. Estimated completion is 2027-01.
What conditions does trial NCT05027906 study?
This clinical trial studies the following conditions: Prevention of Rejection in Kidney Transplant.
What interventions are being tested in trial NCT05027906?
The interventions under investigation include: AT-1501 (DRUG).
Who is sponsoring clinical trial NCT05027906?
This trial is sponsored by Eledon Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027906 being conducted?
This trial has 9 study locations across Ohio, New South Wales, South Australia, British Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05027906's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI